Keisuke Hirano Selected Research

Keisuke Hirano Research Topics

Disease

34	Chronic Limb-Threatening Ischemia 10/2021 - 07/2010
10	Thrombosis (Thrombus) 10/2022 - 02/2012
10	Diabetes Mellitus 03/2021 - 10/2011
7	Myocardial Infarction 01/2022 - 11/2002
7	Ischemia 01/2021 - 04/2013
7	Wounds and Injuries (Trauma) 01/2019 - 02/2015
5	Renal Insufficiency (Renal Failure) 10/2022 - 01/2012
5	Peripheral Arterial Disease 01/2022 - 01/2014
5	Hemorrhage 01/2020 - 04/2016
5	Cardiovascular Diseases (Cardiovascular Disease) 12/2016 - 08/2009
4	Stroke (Strokes) 01/2022 - 01/2012
4	Coronary Artery Disease (Coronary Atherosclerosis) 12/2016 - 06/2014
3	No-Reflow Phenomenon 12/2021 - 01/2017
3	Pathologic Constriction (Stenosis) 02/2020 - 01/2011
2	Atrial Fibrillation 01/2021 - 11/2016
2	AIDS-Related Complex (ARC) 10/2018 - 06/2018
2	Infections 01/2018 - 03/2017
2	Embolism (Embolus) 01/2018 - 05/2017
2	Anemia 11/2017 - 11/2016
2	Hematoma 04/2016 - 06/2014
2	Death (Near-Death Experience) 02/2016 - 02/2012
2	Heart Failure 09/2015 - 02/2013
2	Chronic Kidney Failure (Chronic Renal Failure) 04/2013 - 02/2013
1	Leriche Syndrome 10/2022
1	Ecchymosis 01/2020
1	Malnutrition (Nutritional Deficiencies) 01/2019
1	Wound Infection (Wound Infections) 01/2019
1	Neointima 10/2018
1	Hypertension (High Blood Pressure) 11/2017
1	Ulcer 11/2016
1	Gastrointestinal Hemorrhage (Hematochezia) 04/2016
1	Rupture 04/2016
1	False Aneurysm (Pseudoaneurysm) 04/2016
1	Atherosclerosis 03/2016
1	Hyperemia 01/2016
1	Penetrating Wounds (Penetrating Wound) 12/2015
1	Cardiogenic Shock 11/2015
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2015
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 12/2014
1	Left Ventricular Dysfunction 06/2014
1	Intermittent Claudication 06/2014
1	Arteriosclerosis Obliterans 09/2013
1	Gangrene 02/2013

Drug/Important Bio-Agent (IBA)

8	Cilostazol (Pletal)FDA LinkGeneric 11/2017 - 01/2011
8	omega-Chloroacetophenone (Mace)IBA 09/2017 - 08/2009
3	nitinolIBA 05/2017 - 09/2013
2	Pharmaceutical PreparationsIBA 12/2021 - 01/2017
2	Sirolimus (Rapamycin)FDA Link 04/2016 - 11/2015
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 09/2015 - 10/2013
2	AlbuminsIBA 08/2015 - 04/2013
2	C-Reactive ProteinIBA 04/2013 - 02/2013
1	Phenobarbital (Luminal)FDA Link 10/2022
1	Biomarkers (Surrogate Marker)IBA 10/2021
1	N 30IBA 01/2019
1	Indigo Carmine (Indigo Blue)IBA 01/2019
1	LipidsIBA 10/2018
1	CalciumIBA 06/2018
1	Thrombin FDA Link 01/2018
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 11/2017
1	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 11/2016
1	PapaverineIBA 01/2016
1	Capsules (Microcapsules)IBA 12/2015
1	Indicators and Reagents (Reagents)IBA 12/2015
1	Insulin (Novolin)FDA Link 06/2014
1	Carvedilol (Coreg)FDA LinkGeneric 01/2014
1	Bisoprolol (Concor)FDA LinkGeneric 01/2014
1	CreatinineIBA 06/2013
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2012

Therapy/Procedure

29	Therapeutics 01/2022 - 02/2012
21	Stents 01/2022 - 01/2011
17	Renal Dialysis (Hemodialysis) 03/2021 - 07/2010
13	Surgical Amputation (Amputations) 01/2021 - 01/2012
9	Drug-Eluting Stents 01/2018 - 11/2015
5	Limb Salvage 01/2019 - 03/2012
3	Catheters 01/2020 - 04/2013
3	Endovascular Procedures 05/2017 - 06/2014
2	Punctures 01/2020 - 04/2016
2	Percutaneous Coronary Intervention 12/2016 - 11/2002
1	Transcatheter Aortic Valve Replacement 01/2020
1	Activities of Daily Living (ADL) 08/2018
1	Endovascular Aneurysm Repair 05/2017
1	Vascular Surgical Procedures 03/2017